SCHEMBL822463

SCHEMBL822463

O=C1c2ccc3c4c(ccc(c24)C(=O)N1C1CCCC1)C(=O)N(C1CCCC1)C3=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.54
SMN1; SMN2 Q16637 4/20 0.51
KDM4E B2RXH2 3/20 0.51
HPGD P15428 3/20 0.51
HSD17B10 Q99714 3/20 0.51
NPSR1 Q6W5P4 2/20 0.51
ATM Q13315 1/20 0.51
MAPK1 P28482 2/20 0.48
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
STAT3 P40763 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10261468 0.98 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL10260482 0.98 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL12511989 0.96 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL14075773 0.95 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL822758 0.92 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL6266985 0.90 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL2861936 0.90 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL12512689 0.89 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL2159155 0.87 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL12512825 0.87 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8530270-B2 Methods of preparing semiconductive compositions and devices EASTMAN KODAK COMPANY (US) 2013-09-10 US disclosed
US-8530270-B2 Methods of preparing semiconductive compositions and devices EASTMAN KODAK COMPANY (US) 2013-09-10 US disclosed
US-8450726-B2 Articles containing coatings of amic acid salts EASTMAN KODAK COMPANY (US) 2013-05-28 US disclosed
US-8450726-B2 Articles containing coatings of amic acid salts EASTMAN KODAK COMPANY (US) 2013-05-28 US disclosed
US-8431433-B2 Methods of providing semiconductor layers from amic acid salts EASTMAN KODAK COMPANY (US) 2013-04-30 US disclosed
US-8431433-B2 Methods of providing semiconductor layers from amic acid salts EASTMAN KODAK COMPANY (US) 2013-04-30 US disclosed
US-8411489-B2 Semiconducting devices and methods of preparing EASTMAN KODAK COMPANY (US) 2013-04-02 US disclosed
US-8411489-B2 Semiconducting devices and methods of preparing EASTMAN KODAK COMPANY (US) 2013-04-02 US disclosed
US-8404892-B2 Aromatic amic acid salts and compositions EASTMAN KODAK COMPANY (US) 2013-03-26 US disclosed
US-8404892-B2 Aromatic amic acid salts and compositions EASTMAN KODAK COMPANY (US) 2013-03-26 US disclosed
US-20110269967-A1 AROMATIC AMIC ACIDS OR AMIC ESTERS AND COMPOSITIONS BANK OF AMERICA, N.A., AS AGENT 2011-11-03 US disclosed
US-20110180784-A1 ORGANIC SEMICONDUCTING COMPOSITIONS AND N-TYPE SEMICONDUCTOR DEVICES BANK OF AMERICA, N.A., AS AGENT 2011-07-28 US disclosed
US-20110180784-A1 ORGANIC SEMICONDUCTING COMPOSITIONS AND N-TYPE SEMICONDUCTOR DEVICES BANK OF AMERICA, N.A., AS AGENT 2011-07-28 US disclosed
US-20110183462-A1 METHOD OF MAKING N-TYPE SEMICONDUCTOR DEVICES BANK OF AMERICA, N.A., AS AGENT 2011-07-28 US disclosed
US-20110183462-A1 METHOD OF MAKING N-TYPE SEMICONDUCTOR DEVICES BANK OF AMERICA, N.A., AS AGENT 2011-07-28 US disclosed
WO-2011090953-A1 ORGANIC SEMICONDUCTING COMPOSITIONS AND N-TYPE SEMICONDUCTOR DEVICES EASTMAN KODAK COMPANY (US) 2011-07-28 WO disclosed
US-7422777-B2 N,N′-dicycloalkyl-substituted naphthalene-based tetracarboxylic diimide compounds as n-type semiconductor materials for thin film transistors EASTMAN KODAK COMPANY (US) 2008-09-09 US disclosed
US-7422777-B2 N,N′-dicycloalkyl-substituted naphthalene-based tetracarboxylic diimide compounds as n-type semiconductor materials for thin film transistors EASTMAN KODAK COMPANY (US) 2008-09-09 US disclosed
US-20070116895-A1 N,N'-dicycloalkyl-substituted naphthalene-based tetracarboxylic diimide compounds as n-type semiconductor materials for thin film transistors EASTMAN KODAK COMPANY 2007-05-24 US disclosed
US-20070116895-A1 N,N'-dicycloalkyl-substituted naphthalene-based tetracarboxylic diimide compounds as n-type semiconductor materials for thin film transistors EASTMAN KODAK COMPANY 2007-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269967-A1 AROMATIC AMIC ACIDS OR AMIC ESTERS AND COMPOSITIONS DDC, AADAC, MYOC ALDH1A1 745/4885SMN1; SMN2 2911/4885KDM4E 664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.